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Clozapine is an atypical antipsychotic drug that has 
been commercially marketed since 1990.[1,2] It has 
been shown that clozapine has a higher efficacy than 
typical antipsychotics and is mostly indicated in cases 
of treatment-resistant schizophrenia.[1-4] Besides the 
higher efficacy, clozapine also has a lower incidence of extrapyramidal 
symptoms (EPSs) than the classic neuroleptics.[1-3] 
Common side-effects associated with clozapine use are sedation, 
hypersalivation, tachycardia, constipation and orthostatic hypo-
tension.[1] A life-threatening adverse effect sometimes associated with 
clozapine use is agranulocytosis.[1-3] In patients with a white blood cell 
count (WCC) <3.5 × 109/L, it has been suggested that they should 
not receive clozapine owing to the difficulty of identifying early 
agranulocytosis.[1]
It has long been known that clozapine is associated with weight 
gain[3] and more recently it has also been shown that there is an 
increased risk among clozapine users for developing metabolic 
syndrome.[4-7] It has been suggested that clozapine may have a direct 
effect on glucose regulation, independent of weight gain,[8] and Koller 
et al.[2] suggested a causal relationship between clozapine treatment 
and diabetes. 
Because of the increased risk of cardiovascular-related death in 
patients with metabolic syndrome,[9] this is a serious adverse effect 
of which the prescribing health practitioner should be fully aware. 
Apart from tachycardia and orthostatic hypotension, other more 
severe cardiovascular side-effects of clozapine include QT-interval 
prolongation, cardiomyopathy and myocarditis.[10-11] Pathological QT- 
interval prolongation has been shown previously to be rare with this 
drug.[11] Although relatively low, the incidence of myocarditis and 
cardiomyopathy with clozapine use has been shown to be higher than 
that of the general population.[10] 
Because clozapine is prescribed as chronic medication for 
schizophrenia patients, it is important to be aware of the development 
of side-effects, especially those that would lead to increased mor-
bidity and mortality (e.g. agranulocytosis, prolonged QT-interval 
and metabolic syndrome). To ensure appropriate monitoring and 
rapid diagnosis for individual patients, it is important to know the 
prevalence of these adverse effects in the population group to which 
the patient belongs. This study was done to establish the prevalence 
and severity of the adverse effects of clozapine in patients of Xhosa 
descent, focusing on metabolic effects, prolongation of QT-interval, 
decrease in WCC and the commonly reported adverse effects.
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Background. Clozapine use is known to be associated with significant side-effects, including prolongation of the QT-interval, agranu-
locytosis and metabolic syndrome. However, few data exist on the prevalence of clozapine side-effects in patients of Xhosa descent. 
Objective. To gather data from Xhosa patients with schizophrenia to establish the prevalence of clozapine side-effects in this population. 
Methods. Twenty-nine Xhosa patients with schizophrenia (as per the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)) 
who had been receiving clozapine treatment for >1 year on an outpatient basis were selected for inclusion. All patients were participating 
in a genetics study in the Cape Metropolitan area. The participants were evaluated for the presence of side-effects (tests including an 
electrocardiogram, white blood cell count (WCC) and fasting blood glucose). 
Results. The prevalence of metabolic syndrome was 44.8% (95% confidence interval (CI) 26.7 - 62.9) and of undiagnosed diabetes mellitus 
13.8% (95% CI 1.24 - 26.34). There was a significant association between metabolic syndrome and body mass index (BMI) (p<0.01). The mean 
(SD) WCC was 7.8 × 109/L (2.8), with 3.4% of the subjects having a WCC <3.5 × 109/L. Sedation (82.8%; 95% CI 69.0 - 96.5), hypersalivation 
(79.3%; 95% CI 64.6 - 94.1) and constipation (44.8%; 95% CI 26.7 - 62.9) were common. The mean QT-interval was 373.8 (35.9) ms and 10% 
had a corrected QT-interval >440 ms. There was an association between the duration of clozapine treatment and QT-interval (with Bazett’s 
correction).  
Conclusion. The high prevalence of metabolic syndrome and undiagnosed diabetes mellitus in this sample points to a need to monitor 
glucose levels and BMI on a regular basis. A larger study should be done to accurately quantify the differences in prevalence of side-effects 
between population groups.
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Methods
Patients with schizophrenia (as per the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR)) of Xhosa descent being 
treated as outpatients and using clozapine as the primary treatment 
modality were selected from a large genetics study done in the Cape 
Metropolitan area.[12] Sixty (8.1%) of the 738 Xhosa participants with 
schizophrenia in the genetic study were taking clozapine at time of 
assessment. A convenience sample of 29 (48%) of the 60 participants 
was analysed for this study. Participation was voluntary. Informed 
written consent was obtained from all participants. The study was 
approved by the Health Research Ethics Committee of Stellenbosch 
University. The prerequisites for the study were that the subjects 
needed to be schizophrenia patients of Xhosa descent (defined as 4/4 
grandparents reported as of Xhosa descent) who had been receiving 
clozapine for >1 year and be outpatients at time of assessment.
Demographic, age, treatment duration and treatment dose data were 
collected by means of a structured questionnaire. A family history of 
cardiovascular disease (including hypertension) and a smoking history 
were obtained. Two self-reported questions regarding exercise and 
weight gain were included. Assessment of the degree of sedation was 
based on a scale used to evaluate the efficacy of H1 antihistamines. [13] 
Every patient was asked a question regarding changes to stools 
(constipation defined as lumpy/hard stools, straining or <3 defecations/
week) after the initiation of clozapine. The frequency and severity 
of clozapine-induced hypersalivation was assessed by means of the 
Drooling Severity Scale (DSS),[14] Drooling Frequency Scale (DFS)[14] 
and Toronto Nocturnal Hypersalivation Scale (TNHS).[15] The presence 
and degree of EPSs was assessed by making use of the Extrapyramidal 
Symptom Rating Scale (ESRS).[16]
Metabolic syndrome, for the purpose of this study, was defined 
(according to the International Diabetes Federation (IDF)[9]) as: 
central obesity of ≥94 cm (for men) and ≥80 cm (for women) or body 
mass index (BMI) >30 kg/m2 plus any two of the following: raised 
triglyceride level ≥1.7 mmol/L; reduced high-density lipoprotein 
(HDL) cholesterol level <1.03 mmol/L (for men) and <1.29 mmol/L 
(for women); systolic blood pressure (BP) ≥130 mmHg or diastolic 
BP ≥85 mmHg; raised fasting plasma glucose levels ≥5.6 mmol/L, or 
previously diagnosed type 2 diabetes. Glucose was measured with an 
ambulatory haemoglucose test meter. The pulse rate of the patients 
was measured manually and the BP was determined by means of a 
portable sphygmomanometer. The waist circumference (measured at 
the point midway between the lowest rib and the iliac crest) and BMI 
were determined by means of a tape measure and an electronic scale.
An electrocardiogram (ECG) was done on every patient and 
the QT-interval was measured from the beginning of ventricular 
depolarisation (Q-wave) to the end of ventricular repolarisation (end 
of the T-wave).[10] The corrected QT-interval (QTc) was calculated 
using both Bazett’s and Fridericia’s corrections.[17] Laboratory blood 
tests included triglyceride, HDL cholesterol levels and WCC.
All variables were analysed descriptively. Where applicable, 
frequency distributions for nominal variables, and medians and 
interquartile ranges (IQRs) for continuous variables were calculated. 
Population parameters for both continuous and dichotomous data 
were calculated using 95% confidence interval (CI). Univariate 
analyses were performed to establish which factors were associated 
with metabolic syndrome (as defined above). The Mann-Whitney 
U-test and χ2 test were used depending on whether the data was 
continuous (former) or nominal (latter). Spearman rank order 
correlations were calculated to investigate the association between 
treatment duration, clozapine dose, age and adverse effects of 
clozapine (sedation, constipation, hypersalivation, prolongation of 
QTc-interval, WCC and EPSs). A significance level of 5% was applied 
throughout. All tests were analysed using Statistica version 10 (2012) 
for Windows.
Results
Demographic and clinical data 
All 29 patients had been taking clozapine for >1 year, with a mean 
(SD) dose of 319.8 (158.3) mg/day (median dose 300 mg/day; range 
125 - 900 mg/day). The mean treatment duration was 6.7 (4.2) years 
(range 1 - 15 years). The mean age of the participants was 40.1 (9.9) 
years, and 90% were men. A family history of cardiovascular disease 
was positive in 69% of the patients. The prevalence of metabolic 
syndrome (according to IDF criteria) was 44.8% (95% CI 26.7 - 62.9). 
The mean waist circumference was 95.6 (17.2) cm and the mean BMI 
was 26.4 (4.4) kg/m2. The mean fasting glucose was 5.8 (1.7) mmol/L 
and the prevalence of undiagnosed diabetes mellitus (fasting plasma 
glucose ≥7.0 mmol/L) was 13.8% (95% CI 1.24 - 26.34) (Table 1).
As shown in Table 2, there was a statistically significant association 
between metabolic syndrome and BMI (p=0.005). Metabolic 
syndrome was not associated with clozapine treatment duration, 
dosage, age, smoking or family history of cardiovascular disease.
No statistically significant association was found between raised 
plasma glucose and dosage of clozapine, nor between raised plasma 
glucose and treatment duration. The three most common abnormal 
metabolic parameters (from IDF criteria) were raised systolic BP 
(79.3%; 95% CI 64.6 - 94.0), raised diastolic BP (58.6%; 95% CI 40.7 - 
76.6) and central obesity (55.2%; 95% CI 37.1 - 73.3). The mean WCC 
(Table 3) was 7.8 × 109/L (2.8), with 3.4% (95% CI 0 - 10.1) of the 
patients having a WCC <3.5 × 109/L. The prevalence of sedation was 
82.8% (95% CI 69.0 - 96.5), with 48.3% of the subjects experiencing 
a sedation rating of 10 (‘hard to stay awake’) on the sedation scale.
According to the TNHS, the prevalence of hypersalivation was 
79.3% (95% CI 64.6 - 94.1). The median (IQR) severity of clozapine-
Table 1. Metabolic profile of the study participants treated 
with clozapine (N=29)
Metabolic syndrome (IDF), % 44.8 (95% CI 26.7 - 62.9)
Waist circumference, cm* 95.6 (17.2)
Body mass index, kg/m2* 26.4 (4.4)
Fasting glucose, mmol/L* 5.8 (1.7)
Systolic blood pressure, mmHg* 137.5 (11.4)
Diastolic blood pressure, mmHg* 86.5 (6.6)
Triglyceride, mmol/L* 1.0 (0.6)
High-density lipoprotein, mmol/L* 1.1 (0.5)
Diabetes mellitus, n (%) 4 (13.8)
IDF = International Diabetes Federation, 2006.
*mean (SD).
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induced hypersalivation was 2 (2 - 2) (‘mild, only lips wet’) according 
to the DSS. With the TNHS, the median severity was 1 (1 - 2) 
(‘mild, signs of saliva on pillow’). There was a prevalence of 13.8% 
moderate hypersalivation (‘wet on lips and chin’) and 10.3% severe 
hypersalivation (‘clothing becomes wet’) as measured with the DSS. 
The prevalence of severe hypersalivation according to the TNHS 
(‘frequent soaking of pillow or clothes >3/wk’) was 13.8%, and 
3.4% of the patients reported very severe hypersalivation (‘awakening 
due to hypersalivation’). The median frequency of hypersalivation, 
according to the DFS, was 2 (2 - 2) (occasionally drools). The 
prevalence of frequent drooling (according to the DFS) was 13.8%, 
while the prevalence of constant drooling, as measured with the same 
scale, was 10.3%. The prevalence of constipation, as reported by the 
subjects, was 44.8% (26.7 - 62.9). 
The mean QT-interval was 373.8 (35.9). The mean corrected 
QT-interval was as follows: for Fridericia’s correction (QTcf), the 
mean was 397.7 (30.5), and for Bazett’s correction (QTcb), the mean 
was 411.1 (38.9). The prevalence of QTcf >440 ms was 10.3% (0 - 
21.4), and that of QTcb >440 ms 20.7% (5.9 - 35.4).
The association between the duration of clozapine treatment and 
the QTcb-interval was statistically significant (p=0.008). Duration of 
clozapine treatment was not statistically associated with the QTcf-
interval (p=0.077) nor with the uncorrected QT-interval (p=0.618). 
The age of the patients and the QTc-intervals (with both corrections) 
showed statistically significant associations (Table 2).
The median severity of the EPSs, as assessed by the ESRS, was 
rated as either minimal (1) or absent (0) (Table 3). The prevalence 
of minimal Parkinsonism was 44.8% (26 - 62.9). Of the participants, 
10.3% (0 - 21.4) were assessed to have ‘moderate’ dyskinesia, with 
6.9% (0 - 16.1) having ‘mild’ Parkinsonism as well as ‘mild’ akathesia. 
None of the subjects had severe or extreme ratings for any of the EPSs. 
Besides the association with QTcb-interval, no other statistically 
significant associations were present between clinical variables and 
duration of clozapine treatment, nor was clozapine dosage associated 
with any demographic or clinical variables, including EPSs (Table 2).
Discussion
This report presents the first systematic study to determine the pre-
va lence of metabolic adverse effects in Xhosa patients treated with 
clozapine. Metabolic syndrome was present in almost 45% of patients. 
Table 2. Univariate associations with clozapine (N=29)
Variable t-test/χ2 value
Associations with metabolic syndrome
Age 0.861
Body mass index 0.005*
Dosage of clozapine 0.983
Clozapine treatment duration 0.844
Associations with raised plasma glucose 
(≥7 mmol/L)
Dosage of clozapine 0.194
Clozapine treatment duration 0.817
Associations with clozapine treatment 
duration 
QT-interval 0.618
QTcf-interval 0.077
QTcb-interval 0.008†
Sedation 0.449
Hypersalivation (TNHS) 0.910
Parkinsonism 0.769
Dystonia 0.221
Dyskinesia 0.774
Akathesia 0.539
Associations with dose of clozapine
Sedation 0.451
Hypersalivation (TNHS) 0.142
QTc-interval 0.832
Parkinsonism 0.797
Dystonia 0.679
Dyskinesia 0.567
Akathesia 0.178
Associations with age
QT-interval 0.961
QTcf-interval 0.025†
QTcb-interval 0.010†
QTcf-interval = Fridericia’s correction; QTcb-interval = Bazett’s correction;  
TNHS = Toronto Nocturnal Hypersalivation Scale.
* p<0.01.
† p<0.05.
Table 3. Other adverse effects fwith clozapine (N=29) 
White blood cell count (× 109/L), mean (SD) 7.8 (2.8)
Sedation, n (%) 24 (82.8)
Hypersalivation,* n (%) 23 (79.3)
Hypersalivation severity,† median (IQR) 2 (2 - 2)
Hypersalivation severity,* median (IQR) 1 (1 - 2)
Hypersalivation,‡ median (IQR) 2 (2 - 2)
Constipation, n (%) 13 (44.8)
QT-interval, ms, mean (SD) 373.8 (35.9)
QTcf-interval, ms, mean (SD) 397.7 (30.5)
QTcb-interval, ms, mean (SD) 411.1 (38.9)
EPSs§
Parkinsonism, median (IQR) 1 (0 - 1)
Dystonia, median (IQR) 0 (0 - 0)
Dyskinesia, median (IQR) 0 (0 - 2)
Akathesia, median (IQR) 0 (0 - 1)
SD = standard deviation; IQR = interquartile range; QTcf-interval = Fridericia’s correction; 
QTcb-interval = Bazett’s correction; EPSs = extrapyramidal symptoms.
*According to the Toronto Nocturnal Hypersalivation Scale.
†According to the Drooling Severity Scale.
‡According to the Drooling Frequency Scale.
§According to the Extrapyramidal Symptom Rating Scale (Clinical Global Impression of 
Movement).
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This agrees with previous studies on other ethnic group patients treated 
with clozapine, where similarly high prevalences were reported.[4,5,7] 
The association between BMI and metabolic syndrome illustrated 
here indicates that BMI may predict metabolic syndrome in clozapine 
users of Xhosa descent. It has been hypothesised that weight gain 
is the most significant contributing factor to the development of 
metabolic syndrome[5] and therefore the BMI may offer a screening test 
for metabolic syndrome in patients treated with clozapine.[18]  
The prevalence of undiagnosed diabetes mellitus was 13.8%, 
consistent with that found in the literature.[19] However, there was no 
association between raised plasma glucose and either clozapine dosage 
or duration of clozapine treatment. Therefore, a direct diabetogenic 
effect of clozapine could not be proven by these data, despite previous 
reports in other population groups suggesting such a direct effect.[8,20] 
It is possible that the high incidence of undiagnosed diabetes in our 
group may be attributable to other factors (e.g. family history, physical 
inactivity, abdominal obesity, poor diet). Because these risk factors for 
diabetes were not controlled for, the use of a comparison group would 
be necessary to confirm this relation.
Previous research has indicated that agranulocytosis can be attributed 
to clozapine use.[1,3] Although a small percentage of subjects in this study 
did have a WCC of <3.5 × 109/L, the study sample was not of sufficient 
size to indicate adequately this rare but dangerous adverse effect. 
Sedation was a side-effect in the majority of patients (>80%) and 
almost half of the patients reported severe sedation (‘hard to stay 
awake’). A high prevalence of hypersalivation was also present, and 
although most subjects only reported a mild degree, this adverse 
effect is very common (almost 80% according to TNHS). Subjects 
also reported a high prevalence of constipation, with over 40% 
affirming the presence of constipation with concurrent clozapine use 
in the absence of laxative use. Healthcare workers are encouraged to 
monitor and treat these side-effects as effectively as possible. 
QT-interval prolongation has been shown to increase cardiac 
arrhythmia risk, especially torsades de pointes and with QT-interval 
prolongation. [10] Although there is no universal upper limit for a normal 
QTc-interval, intervals >440 ms are considered to be prolonged.[10] 
Some studies have reported that patients with QTc-intervals >440 
ms had an increased risk of mortality,[21,22] but it appears that there is 
some controversy. However, in this study, the high prevalence (20.7%) 
of pro longed QTc-intervals (>440 ms) with Bazett’s correction, and 
a prevalence of 10.3% with Fridericia’s correction, may indicate an 
increased risk for QT-interval prolongation with clozapine use. The 
association between the QTcb-interval and duration of clozapine 
treat ment further illustrates the possibility of increased risk. This dose-
related effect of clozapine has also been reported in other population 
groups. [11] Prolongation of the QT-interval is known to be associated 
with increased age,[23] which was true for this population group studied. 
A low prevalence of severe extrapyramidal adverse effects was found 
in this group as would be expected with atypical antipsychotic drugs. 
Limitations of the study include: the cross-sectional design of this 
study did not allow us to comment on the possible interplay between 
treatment adherence over time and the metabolic effects of that 
treatment. In addition, the results cannot be extrapolated to other 
ethnic groups in South Africa as differences in genetic predisposition 
and lifestyle patterns may lead to interethnic variation. 
Conclusion
The findings from this study are consistent with those from previous 
research, linking metabolic syndrome to clozapine treatment[4,5,7] in 
other population groups. These results reiterate the necessity to monitor 
weight and BMI in patients receiving clozapine treatment. The rela-
tively high prevalence of undiagnosed diabetes mellitus in this group 
may further point to a need to monitor glucose levels on a regular basis 
in these patients. The presence of a reasonable proportion of patients 
with abnormal QTc-intervals indicates the requirement of regular 
ECG monitoring in this patient group, especially in elderly patients. 
The high prevalence of the less serious side-effects of clozapine in this 
group illustrates the necessity to educate patients regarding treatment 
compliance. Because of the cross-sectional design of this study, there 
was no long-term follow-up of patients. This, as well as the use of 
comparative data with randomised assignment and detailed monitoring 
of concomitant medication use, is recommended for future research, 
especially with regard to the metabolic adverse effects of clozapine.
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